

Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2024(Status and Outlook)

<https://marketpublishers.com/r/G6122E16A4AAEN.html>

Date: February 2024

Pages: 164

Price: US\$ 3,200.00 (Single User License)

ID: G6122E16A4AAEN

Abstracts

Report Overview

This report provides a deep insight into the global Drugs for Non-Small Cell Lung Cancer market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Drugs for Non-Small Cell Lung Cancer Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Drugs for Non-Small Cell Lung Cancer market in any manner.

Global Drugs for Non-Small Cell Lung Cancer Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding

the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Bristol-Myers Squibb

GlaxoSmithKline

Menarini

Sanofi

Ziopharm Oncology

Alchemia

Amgen

Apotex

BioMarin Pharmaceutical

CellAct Pharma

Cerulean Pharma

Cipla

Cornerstone Pharmaceuticals

Curis

CytRx

Eli Lilly

Exelixis

Fresenius Kabi

Genentech

Hikma Pharmaceuticals

Hospira

Intas Pharmaceuticals

Karyopharm Therapeutics

Kyowa Hakko Kirin

Ligand Pharmaceuticals

Market Segmentation (by Type)

Radiofrequency Ablation (RFA)

Radiation Therapy

Chemotherapy

Targeted Therapies

Immunotherapy

Market Segmentation (by Application)

Hospitals

Clinics

Other

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Drugs for Non-Small Cell Lung Cancer Market

Overview of the regional outlook of the Drugs for Non-Small Cell Lung Cancer Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Drugs for Non-Small Cell Lung Cancer Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Drugs for Non-Small Cell Lung Cancer
- 1.2 Key Market Segments
 - 1.2.1 Drugs for Non-Small Cell Lung Cancer Segment by Type
 - 1.2.2 Drugs for Non-Small Cell Lung Cancer Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) Estimates and Forecasts (2019-2030)
 - 2.1.2 Global Drugs for Non-Small Cell Lung Cancer Sales Estimates and Forecasts (2019-2030)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET COMPETITIVE LANDSCAPE

- 3.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Manufacturers (2019-2024)
- 3.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Manufacturers (2019-2024)
- 3.3 Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.4 Global Drugs for Non-Small Cell Lung Cancer Average Price by Manufacturers (2019-2024)
- 3.5 Manufacturers Drugs for Non-Small Cell Lung Cancer Sales Sites, Area Served, Product Type
- 3.6 Drugs for Non-Small Cell Lung Cancer Market Competitive Situation and Trends
 - 3.6.1 Drugs for Non-Small Cell Lung Cancer Market Concentration Rate

3.6.2 Global 5 and 10 Largest Drugs for Non-Small Cell Lung Cancer Players Market Share by Revenue

3.6.3 Mergers & Acquisitions, Expansion

4 DRUGS FOR NON-SMALL CELL LUNG CANCER INDUSTRY CHAIN ANALYSIS

4.1 Drugs for Non-Small Cell Lung Cancer Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

4.3 Midstream Market Analysis

4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET

5.1 Key Development Trends

5.2 Driving Factors

5.3 Market Challenges

5.4 Market Restraints

5.5 Industry News

5.5.1 New Product Developments

5.5.2 Mergers & Acquisitions

5.5.3 Expansions

5.5.4 Collaboration/Supply Contracts

5.6 Industry Policies

6 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)

6.2 Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type (2019-2024)

6.3 Global Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2019-2024)

6.4 Global Drugs for Non-Small Cell Lung Cancer Price by Type (2019-2024)

7 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)

7.2 Global Drugs for Non-Small Cell Lung Cancer Market Sales by Application (2019-2024)

7.3 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) by Application (2019-2024)

7.4 Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)

8 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET SEGMENTATION BY REGION

8.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Region

8.1.1 Global Drugs for Non-Small Cell Lung Cancer Sales by Region

8.1.2 Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region

8.2 North America

8.2.1 North America Drugs for Non-Small Cell Lung Cancer Sales by Country

8.2.2 U.S.

8.2.3 Canada

8.2.4 Mexico

8.3 Europe

8.3.1 Europe Drugs for Non-Small Cell Lung Cancer Sales by Country

8.3.2 Germany

8.3.3 France

8.3.4 U.K.

8.3.5 Italy

8.3.6 Russia

8.4 Asia Pacific

8.4.1 Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales by Region

8.4.2 China

8.4.3 Japan

8.4.4 South Korea

8.4.5 India

8.4.6 Southeast Asia

8.5 South America

8.5.1 South America Drugs for Non-Small Cell Lung Cancer Sales by Country

8.5.2 Brazil

8.5.3 Argentina

8.5.4 Columbia

8.6 Middle East and Africa

8.6.1 Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales by Region

8.6.2 Saudi Arabia

8.6.3 UAE

8.6.4 Egypt

8.6.5 Nigeria

8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Bristol-Myers Squibb

9.1.1 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Basic Information

9.1.2 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Overview

9.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.1.4 Bristol-Myers Squibb Business Overview

9.1.5 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer SWOT Analysis

9.1.6 Bristol-Myers Squibb Recent Developments

9.2 GlaxoSmithKline

9.2.1 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Basic Information

9.2.2 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Overview

9.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.2.4 GlaxoSmithKline Business Overview

9.2.5 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer SWOT Analysis

9.2.6 GlaxoSmithKline Recent Developments

9.3 Menarini

9.3.1 Menarini Drugs for Non-Small Cell Lung Cancer Basic Information

9.3.2 Menarini Drugs for Non-Small Cell Lung Cancer Product Overview

9.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.3.4 Menarini Drugs for Non-Small Cell Lung Cancer SWOT Analysis

9.3.5 Menarini Business Overview

9.3.6 Menarini Recent Developments

9.4 Sanofi

9.4.1 Sanofi Drugs for Non-Small Cell Lung Cancer Basic Information

9.4.2 Sanofi Drugs for Non-Small Cell Lung Cancer Product Overview

9.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.4.4 Sanofi Business Overview

9.4.5 Sanofi Recent Developments

9.5 Ziopharm Oncology

9.5.1 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Basic Information

- 9.5.2 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Overview
- 9.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Market Performance
- 9.5.4 Ziopharm Oncology Business Overview
- 9.5.5 Ziopharm Oncology Recent Developments
- 9.6 Alchemia
 - 9.6.1 Alchemia Drugs for Non-Small Cell Lung Cancer Basic Information
 - 9.6.2 Alchemia Drugs for Non-Small Cell Lung Cancer Product Overview
 - 9.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Product Market Performance
 - 9.6.4 Alchemia Business Overview
 - 9.6.5 Alchemia Recent Developments
- 9.7 Amgen
 - 9.7.1 Amgen Drugs for Non-Small Cell Lung Cancer Basic Information
 - 9.7.2 Amgen Drugs for Non-Small Cell Lung Cancer Product Overview
 - 9.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Product Market Performance
 - 9.7.4 Amgen Business Overview
 - 9.7.5 Amgen Recent Developments
- 9.8 Apotex
 - 9.8.1 Apotex Drugs for Non-Small Cell Lung Cancer Basic Information
 - 9.8.2 Apotex Drugs for Non-Small Cell Lung Cancer Product Overview
 - 9.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Product Market Performance
 - 9.8.4 Apotex Business Overview
 - 9.8.5 Apotex Recent Developments
- 9.9 BioMarin Pharmaceutical
 - 9.9.1 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Basic Information
 - 9.9.2 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Overview
 - 9.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Market Performance
 - 9.9.4 BioMarin Pharmaceutical Business Overview
 - 9.9.5 BioMarin Pharmaceutical Recent Developments
- 9.10 CellAct Pharma
 - 9.10.1 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
 - 9.10.2 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
 - 9.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Market Performance
 - 9.10.4 CellAct Pharma Business Overview
 - 9.10.5 CellAct Pharma Recent Developments

9.11 Cerulean Pharma

- 9.11.1 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Basic Information
- 9.11.2 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Overview
- 9.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Market

Performance

- 9.11.4 Cerulean Pharma Business Overview
- 9.11.5 Cerulean Pharma Recent Developments

9.12 Cipla

- 9.12.1 Cipla Drugs for Non-Small Cell Lung Cancer Basic Information
- 9.12.2 Cipla Drugs for Non-Small Cell Lung Cancer Product Overview
- 9.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Product Market Performance
- 9.12.4 Cipla Business Overview
- 9.12.5 Cipla Recent Developments

9.13 Cornerstone Pharmaceuticals

9.13.1 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

9.13.2 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

9.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance

- 9.13.4 Cornerstone Pharmaceuticals Business Overview
- 9.13.5 Cornerstone Pharmaceuticals Recent Developments

9.14 Curis

- 9.14.1 Curis Drugs for Non-Small Cell Lung Cancer Basic Information
- 9.14.2 Curis Drugs for Non-Small Cell Lung Cancer Product Overview
- 9.14.3 Curis Drugs for Non-Small Cell Lung Cancer Product Market Performance
- 9.14.4 Curis Business Overview
- 9.14.5 Curis Recent Developments

9.15 CytRx

- 9.15.1 CytRx Drugs for Non-Small Cell Lung Cancer Basic Information
- 9.15.2 CytRx Drugs for Non-Small Cell Lung Cancer Product Overview
- 9.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Product Market Performance
- 9.15.4 CytRx Business Overview
- 9.15.5 CytRx Recent Developments

9.16 Eli Lilly

- 9.16.1 Eli Lilly Drugs for Non-Small Cell Lung Cancer Basic Information
- 9.16.2 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Overview
- 9.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Market Performance
- 9.16.4 Eli Lilly Business Overview

9.16.5 Eli Lilly Recent Developments

9.17 Exelixis

9.17.1 Exelixis Drugs for Non-Small Cell Lung Cancer Basic Information

9.17.2 Exelixis Drugs for Non-Small Cell Lung Cancer Product Overview

9.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.17.4 Exelixis Business Overview

9.17.5 Exelixis Recent Developments

9.18 Fresenius Kabi

9.18.1 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Basic Information

9.18.2 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Overview

9.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Market

Performance

9.18.4 Fresenius Kabi Business Overview

9.18.5 Fresenius Kabi Recent Developments

9.19 Genentech

9.19.1 Genentech Drugs for Non-Small Cell Lung Cancer Basic Information

9.19.2 Genentech Drugs for Non-Small Cell Lung Cancer Product Overview

9.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.19.4 Genentech Business Overview

9.19.5 Genentech Recent Developments

9.20 Hikma Pharmaceuticals

9.20.1 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

9.20.2 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

9.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.20.4 Hikma Pharmaceuticals Business Overview

9.20.5 Hikma Pharmaceuticals Recent Developments

9.21 Hospira

9.21.1 Hospira Drugs for Non-Small Cell Lung Cancer Basic Information

9.21.2 Hospira Drugs for Non-Small Cell Lung Cancer Product Overview

9.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.21.4 Hospira Business Overview

9.21.5 Hospira Recent Developments

9.22 Intas Pharmaceuticals

9.22.1 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

9.22.2 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

9.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market

Performance

9.22.4 Intas Pharmaceuticals Business Overview

9.22.5 Intas Pharmaceuticals Recent Developments

9.23 Karyopharm Therapeutics

9.23.1 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Basic Information

9.23.2 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Overview

9.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.23.4 Karyopharm Therapeutics Business Overview

9.23.5 Karyopharm Therapeutics Recent Developments

9.24 Kyowa Hakko Kirin

9.24.1 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Basic Information

9.24.2 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Overview

9.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.24.4 Kyowa Hakko Kirin Business Overview

9.24.5 Kyowa Hakko Kirin Recent Developments

9.25 Ligand Pharmaceuticals

9.25.1 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

9.25.2 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

9.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Market Performance

9.25.4 Ligand Pharmaceuticals Business Overview

9.25.5 Ligand Pharmaceuticals Recent Developments

10 DRUGS FOR NON-SMALL CELL LUNG CANCER MARKET FORECAST BY REGION

10.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast

10.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Region

10.2.1 North America Market Size Forecast by Country

10.2.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country

10.2.3 Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region

10.2.4 South America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country

10.2.5 Middle East and Africa Forecasted Consumption of Drugs for Non-Small Cell Lung Cancer by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)

11.1 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Type (2025-2030)

11.1.1 Global Forecasted Sales of Drugs for Non-Small Cell Lung Cancer by Type (2025-2030)

11.1.2 Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2025-2030)

11.1.3 Global Forecasted Price of Drugs for Non-Small Cell Lung Cancer by Type (2025-2030)

11.2 Global Drugs for Non-Small Cell Lung Cancer Market Forecast by Application (2025-2030)

11.2.1 Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) Forecast by Application

11.2.2 Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) Forecast by Application (2025-2030)

12 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type

Table 2. Introduction of the Application

Table 3. Market Size (M USD) Segment Executive Summary

Table 4. Drugs for Non-Small Cell Lung Cancer Market Size Comparison by Region (M USD)

Table 5. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Manufacturers (2019-2024)

Table 6. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Manufacturers (2019-2024)

Table 7. Global Drugs for Non-Small Cell Lung Cancer Revenue (M USD) by Manufacturers (2019-2024)

Table 8. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Manufacturers (2019-2024)

Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2022)

Table 10. Global Market Drugs for Non-Small Cell Lung Cancer Average Price (USD/Unit) of Key Manufacturers (2019-2024)

Table 11. Manufacturers Drugs for Non-Small Cell Lung Cancer Sales Sites and Area Served

Table 12. Manufacturers Drugs for Non-Small Cell Lung Cancer Product Type

Table 13. Global Drugs for Non-Small Cell Lung Cancer Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Mergers & Acquisitions, Expansion Plans

Table 15. Industry Chain Map of Drugs for Non-Small Cell Lung Cancer

Table 16. Market Overview of Key Raw Materials

Table 17. Midstream Market Analysis

Table 18. Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Drugs for Non-Small Cell Lung Cancer Market Challenges

Table 22. Global Drugs for Non-Small Cell Lung Cancer Sales by Type (K Units)

Table 23. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (M USD)

Table 24. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Type (2019-2024)

Table 25. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Type

(2019-2024)

Table 26. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) by Type (2019-2024)

Table 27. Global Drugs for Non-Small Cell Lung Cancer Market Size Share by Type (2019-2024)

Table 28. Global Drugs for Non-Small Cell Lung Cancer Price (USD/Unit) by Type (2019-2024)

Table 29. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) by Application

Table 30. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application

Table 31. Global Drugs for Non-Small Cell Lung Cancer Sales by Application (2019-2024) & (K Units)

Table 32. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application (2019-2024)

Table 33. Global Drugs for Non-Small Cell Lung Cancer Sales by Application (2019-2024) & (M USD)

Table 34. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2019-2024)

Table 35. Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)

Table 36. Global Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)

Table 37. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region (2019-2024)

Table 38. North America Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)

Table 39. Europe Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)

Table 40. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)

Table 41. South America Drugs for Non-Small Cell Lung Cancer Sales by Country (2019-2024) & (K Units)

Table 42. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales by Region (2019-2024) & (K Units)

Table 43. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Basic Information

Table 44. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product Overview

Table 45. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

- Table 46. Bristol-Myers Squibb Business Overview
- Table 47. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer SWOT Analysis
- Table 48. Bristol-Myers Squibb Recent Developments
- Table 49. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Basic Information
- Table 50. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product Overview
- Table 51. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 52. GlaxoSmithKline Business Overview
- Table 53. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer SWOT Analysis
- Table 54. GlaxoSmithKline Recent Developments
- Table 55. Menarini Drugs for Non-Small Cell Lung Cancer Basic Information
- Table 56. Menarini Drugs for Non-Small Cell Lung Cancer Product Overview
- Table 57. Menarini Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 58. Menarini Drugs for Non-Small Cell Lung Cancer SWOT Analysis
- Table 59. Menarini Business Overview
- Table 60. Menarini Recent Developments
- Table 61. Sanofi Drugs for Non-Small Cell Lung Cancer Basic Information
- Table 62. Sanofi Drugs for Non-Small Cell Lung Cancer Product Overview
- Table 63. Sanofi Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 64. Sanofi Business Overview
- Table 65. Sanofi Recent Developments
- Table 66. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Basic Information
- Table 67. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product Overview
- Table 68. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 69. Ziopharm Oncology Business Overview
- Table 70. Ziopharm Oncology Recent Developments
- Table 71. Alchemia Drugs for Non-Small Cell Lung Cancer Basic Information
- Table 72. Alchemia Drugs for Non-Small Cell Lung Cancer Product Overview
- Table 73. Alchemia Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)
- Table 74. Alchemia Business Overview
- Table 75. Alchemia Recent Developments
- Table 76. Amgen Drugs for Non-Small Cell Lung Cancer Basic Information
- Table 77. Amgen Drugs for Non-Small Cell Lung Cancer Product Overview
- Table 78. Amgen Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 79. Amgen Business Overview

Table 80. Amgen Recent Developments

Table 81. Apotex Drugs for Non-Small Cell Lung Cancer Basic Information

Table 82. Apotex Drugs for Non-Small Cell Lung Cancer Product Overview

Table 83. Apotex Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 84. Apotex Business Overview

Table 85. Apotex Recent Developments

Table 86. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Basic Information

Table 87. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product Overview

Table 88. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 89. BioMarin Pharmaceutical Business Overview

Table 90. BioMarin Pharmaceutical Recent Developments

Table 91. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Basic Information

Table 92. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product Overview

Table 93. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 94. CellAct Pharma Business Overview

Table 95. CellAct Pharma Recent Developments

Table 96. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Basic Information

Table 97. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product Overview

Table 98. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 99. Cerulean Pharma Business Overview

Table 100. Cerulean Pharma Recent Developments

Table 101. Cipla Drugs for Non-Small Cell Lung Cancer Basic Information

Table 102. Cipla Drugs for Non-Small Cell Lung Cancer Product Overview

Table 103. Cipla Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 104. Cipla Business Overview

Table 105. Cipla Recent Developments

Table 106. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

Table 107. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

Table 108. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales

(K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 109. Cornerstone Pharmaceuticals Business Overview

Table 110. Cornerstone Pharmaceuticals Recent Developments

Table 111. Curis Drugs for Non-Small Cell Lung Cancer Basic Information

Table 112. Curis Drugs for Non-Small Cell Lung Cancer Product Overview

Table 113. Curis Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 114. Curis Business Overview

Table 115. Curis Recent Developments

Table 116. CytRx Drugs for Non-Small Cell Lung Cancer Basic Information

Table 117. CytRx Drugs for Non-Small Cell Lung Cancer Product Overview

Table 118. CytRx Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 119. CytRx Business Overview

Table 120. CytRx Recent Developments

Table 121. Eli Lilly Drugs for Non-Small Cell Lung Cancer Basic Information

Table 122. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product Overview

Table 123. Eli Lilly Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 124. Eli Lilly Business Overview

Table 125. Eli Lilly Recent Developments

Table 126. Exelixis Drugs for Non-Small Cell Lung Cancer Basic Information

Table 127. Exelixis Drugs for Non-Small Cell Lung Cancer Product Overview

Table 128. Exelixis Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 129. Exelixis Business Overview

Table 130. Exelixis Recent Developments

Table 131. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Basic Information

Table 132. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product Overview

Table 133. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 134. Fresenius Kabi Business Overview

Table 135. Fresenius Kabi Recent Developments

Table 136. Genentech Drugs for Non-Small Cell Lung Cancer Basic Information

Table 137. Genentech Drugs for Non-Small Cell Lung Cancer Product Overview

Table 138. Genentech Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 139. Genentech Business Overview

Table 140. Genentech Recent Developments

Table 141. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

Table 142. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

Table 143. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 144. Hikma Pharmaceuticals Business Overview

Table 145. Hikma Pharmaceuticals Recent Developments

Table 146. Hospira Drugs for Non-Small Cell Lung Cancer Basic Information

Table 147. Hospira Drugs for Non-Small Cell Lung Cancer Product Overview

Table 148. Hospira Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 149. Hospira Business Overview

Table 150. Hospira Recent Developments

Table 151. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

Table 152. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product Overview

Table 153. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 154. Intas Pharmaceuticals Business Overview

Table 155. Intas Pharmaceuticals Recent Developments

Table 156. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Basic Information

Table 157. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product Overview

Table 158. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 159. Karyopharm Therapeutics Business Overview

Table 160. Karyopharm Therapeutics Recent Developments

Table 161. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Basic Information

Table 162. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product Overview

Table 163. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 164. Kyowa Hakko Kirin Business Overview

Table 165. Kyowa Hakko Kirin Recent Developments

Table 166. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Basic Information

Table 167. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product

Overview

Table 168. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Sales (K Units), Revenue (M USD), Price (USD/Unit) and Gross Margin (2019-2024)

Table 169. Ligand Pharmaceuticals Business Overview

Table 170. Ligand Pharmaceuticals Recent Developments

Table 171. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Region (2025-2030) & (K Units)

Table 172. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2025-2030) & (M USD)

Table 173. North America Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)

Table 174. North America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 175. Europe Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)

Table 176. Europe Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 177. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Forecast by Region (2025-2030) & (K Units)

Table 178. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Region (2025-2030) & (M USD)

Table 179. South America Drugs for Non-Small Cell Lung Cancer Sales Forecast by Country (2025-2030) & (K Units)

Table 180. South America Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 181. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Consumption Forecast by Country (2025-2030) & (Units)

Table 182. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Country (2025-2030) & (M USD)

Table 183. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Type (2025-2030) & (K Units)

Table 184. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Type (2025-2030) & (M USD)

Table 185. Global Drugs for Non-Small Cell Lung Cancer Price Forecast by Type (2025-2030) & (USD/Unit)

Table 186. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) Forecast by Application (2025-2030)

Table 187. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Application (2025-2030) & (M USD)

List Of Figures

LIST OF FIGURES

Figure 1. Product Picture of Drugs for Non-Small Cell Lung Cancer

Figure 2. Data Triangulation

Figure 3. Key Caveats

Figure 4. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD), 2019-2030

Figure 5. Global Drugs for Non-Small Cell Lung Cancer Market Size (M USD) (2019-2030)

Figure 6. Global Drugs for Non-Small Cell Lung Cancer Sales (K Units) & (2019-2030)

Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 9. Evaluation Matrix of Regional Market Development Potential

Figure 10. Drugs for Non-Small Cell Lung Cancer Market Size by Country (M USD)

Figure 11. Drugs for Non-Small Cell Lung Cancer Sales Share by Manufacturers in 2023

Figure 12. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Manufacturers in 2023

Figure 13. Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023

Figure 14. Global Market Drugs for Non-Small Cell Lung Cancer Average Price (USD/Unit) of Key Manufacturers in 2023

Figure 15. The Global 5 and 10 Largest Players: Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2023

Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 17. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type

Figure 18. Sales Market Share of Drugs for Non-Small Cell Lung Cancer by Type (2019-2024)

Figure 19. Sales Market Share of Drugs for Non-Small Cell Lung Cancer by Type in 2023

Figure 20. Market Size Share of Drugs for Non-Small Cell Lung Cancer by Type (2019-2024)

Figure 21. Market Size Market Share of Drugs for Non-Small Cell Lung Cancer by Type in 2023

Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 23. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application

Figure 24. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by

Application (2019-2024)

Figure 25. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Application in 2023

Figure 26. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application (2019-2024)

Figure 27. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application in 2023

Figure 28. Global Drugs for Non-Small Cell Lung Cancer Sales Growth Rate by Application (2019-2024)

Figure 29. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region (2019-2024)

Figure 30. North America Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 31. North America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023

Figure 32. U.S. Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 33. Canada Drugs for Non-Small Cell Lung Cancer Sales (K Units) and Growth Rate (2019-2024)

Figure 34. Mexico Drugs for Non-Small Cell Lung Cancer Sales (Units) and Growth Rate (2019-2024)

Figure 35. Europe Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 36. Europe Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023

Figure 37. Germany Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 38. France Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 39. U.K. Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 40. Italy Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 41. Russia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 42. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)

Figure 43. Asia Pacific Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region in 2023

Figure 44. China Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 45. Japan Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 46. South Korea Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 47. India Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 48. Southeast Asia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 49. South America Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)

Figure 50. South America Drugs for Non-Small Cell Lung Cancer Sales Market Share by Country in 2023

Figure 51. Brazil Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 52. Argentina Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 53. Columbia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 54. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (K Units)

Figure 55. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Sales Market Share by Region in 2023

Figure 56. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 57. UAE Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 58. Egypt Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 59. Nigeria Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 60. South Africa Drugs for Non-Small Cell Lung Cancer Sales and Growth Rate (2019-2024) & (K Units)

Figure 61. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Volume (2019-2030) & (K Units)

Figure 62. Global Drugs for Non-Small Cell Lung Cancer Market Size Forecast by Value (2019-2030) & (M USD)

Figure 63. Global Drugs for Non-Small Cell Lung Cancer Sales Market Share Forecast

by Type (2025-2030)

Figure 64. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Type (2025-2030)

Figure 65. Global Drugs for Non-Small Cell Lung Cancer Sales Forecast by Application (2025-2030)

Figure 66. Global Drugs for Non-Small Cell Lung Cancer Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Drugs for Non-Small Cell Lung Cancer Market Research Report 2024(Status and Outlook)

Product link: <https://marketpublishers.com/r/G6122E16A4AAEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6122E16A4AAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

